Self-expanding TAVR system shows durable benefits in low-ris

Self-expanding TAVR system shows durable benefits in low-risk patients at 3 years

NEW ORLEANS — At 3 years, patients with severe aortic stenosis at low surgical risk who had transcatheter aortic valve replacement with a self-expanding valve continued to have lower risk for death or stroke than those who had surgical AVR. In the main results of the Evolut Low Risk Trial, risk for all-cause mortality or disabling stroke at 2 years was numerically lower and noninferior in

Related Keywords

Johnk Forrest , Katie Kalvaitis , Byerik Swain , Edwards Lifesciences , Amye Simone , American College Of Cardiology Scientific Session , Journal Of The American College Cardiology , Yale University School Of Medicine , Medtronic , Yale New Haven Health System , American College , New England Journal , Medicine Late Breaking Clinical , Cardiology Scientific Session , New Orleans , Evolut Low Risk Trial , Yale University School , Cardiology Scientific ,

© 2025 Vimarsana